Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.33 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731378 | 0.85 | MMP2 (0.39) | CA12MMP2KDM4ETHRBMAPK1 | |
| SCHEMBL10613308 | 0.84 | ANPEP (0.34) | CA12MMP2ALDH1A1KDM4ETHRB | |
| SCHEMBL8656785 | 0.81 | MEN1 (0.32) | MMP2MEN1USP2ALDH1A1MAPT | |
| SCHEMBL18825604 | 0.80 | CNR1 (0.36) | CA12CA9ANPEPCA1CA2 | |
| SCHEMBL17187190 | 0.78 | S1PR2 (0.40) | CA12MMP2KDM4ETHRBMAPK1 | |
| SCHEMBL6129832 | 0.77 | MEN1 (0.30) | MEN1USP2ALDH1A1MAPTKMT2A | |
| (Propylamino)Methylenediphosphonic Acid SCHEMBL8817761 | 0.76 | MMP2 (0.50) | MMP2ANPEPMMP9ERAP2 | |
| SCHEMBL9711407 | 0.76 | TYMS (0.35) | CA12MMP2KDM4ETHRBMAPK1 | |
| SCHEMBL1496455 | 0.75 | GABBR2 (0.33) | — | |
| Methane SCHEMBL10936621 | 0.74 | MMP2 (0.35) | CA12MMP2KDM4ETHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3959458-A | PHOSPHONATE OR AMINO-PHOSPHORUS COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-05-25 | — | — | US | claimed |
| US-20210140945-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES AND DISORDERS | MADRIGAL PHARMACEUTICALS INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180217130-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | MADRIGAL PHARMACEUTICALS INC (US) | 2018-08-02 | — | — | US | disclosed |
| US-9910031-B2 | Compositions and methods for modulating c-Rel-dependent cytokine production | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-4216212-A | Pyrazolidine anti-inflammatory composition and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| EP-0001310-A1 | Low phosphate detergent composition for fabric washing | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-04 | — | — | EP | disclosed |
| US-4137309-A | SICKLE CELL ANEMIA, GEMINAL DIPHOSPHONATE | THE PROCTER & GAMBLE COMPANY (US) | 1979-01-30 | — | — | US | disclosed |
| US-4100067-A | AMINO-PHOSPHONIC ACIDS | BENCKISER-KNAPSACK GMBH. (DE) | 1978-07-11 | — | — | US | disclosed |
| US-4067971-A | ORGANOPHOSPHONATE COMPOUNDS, TREATMENT OF HYPOXIA, ISCHEMIC TISSUE DISEASES | THE PROCTER & GAMBLE COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-4029696-A | SEQUESTERANTS | BENCKISER-KNAPSACK GMBH (DT) | 1977-06-14 | — | — | US | disclosed |
| US-4025616-A | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies | THE PROCTER & GAMBLE COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-RE29182-E | POLYPHOSPHONIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-3959458-A | PHOSPHONATE OR AMINO-PHOSPHORUS COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
| US-3934002-A | BIS-GUANIDE | THE PROCTER & GAMBLE COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | CA12 3833/4885MMP2 4041/4885MEN1 335/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | CA12 3240/4885MMP2 2299/4885MEN1 3157/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | CA12 3223/4885MMP2 2229/4885MEN1 3151/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | CA12 3833/4885MMP2 4041/4885MEN1 335/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | CA12 3833/4885MMP2 4041/4885MEN1 335/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | CA12 3240/4885MMP2 2299/4885MEN1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.